Moderna Inc. shares declined after the company’s first-quarter vaccine sales missed estimates and it disclosed a delay in the ...

Kennedy and FDA Commissioner Marty Makary’s approach to assessing vaccines could put Covid boosters out of reach.

The department did not confirm which vaccines the testing would be applied to or how the change would be implemented.

Jefferies analysts said Moderna’s first quarter was “in line,” with a miss on revenue offset by a beat on earnings per share.

From STAT’s Jason Mast: Moderna said this morning in its earnings report it planned to cut costs by around $1.5 billion by ...

“Under Secretary Kennedy’s leadership, all new vaccines will undergo safety testing in placebo-controlled trials prior to ...

Several current and former FDA employees who spoke to Inside Medicine on the condition of anonymity have come to see the ...

UB researchers have compiled a list of words physicians should never say to patients with complex, chronic disorders that are ...

How have the wild initial months of Donald Trump’s return to the White House landed on Washington? We asked the people who ...

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

The U.S. FDA is planning to require all new vaccines to undergo placebo-controlled trials before approval. Read more here.

After President Trump’s first nominee to lead the Centers for Disease Control and Prevention (CDC) failed to gain traction ...